Glioblastoma multiforme (GBM) cells frequently harbor amplification and/or gain-of-function mutation of the EGFR gene leading to the activation of multiple signaling pathways. Blockade of EGFR activation inhibited the activation of both AKT and Stat3 in U87 and D54 GBM cells and induced spontaneous apoptosis, which were associated with reduction in the steady-state level of Mcl-1. Surprisingly, inhibition of PI3 kinase (PI3K) activity, which in turn inhibited AKT activation, significantly increased the DNA-binding activity of Stat3 in U87 and D54 cells. This was not due to an increase in the level of tyrosine-phosphorylated Stat3. Conversely, ectopic expression of constitutively activated AKT significantly decreased the DNA-binding activity of Stat3 in 293T cells. Interestingly, blockade of protein phosphatase 2A activity in GBM or 293T cells by calyculin A, which activated AKT, stabilized the phosphorylation of multiple Ser/Thr residues that were located in the transactivation domain (TAD) of Stat3 and this in turn completely ablated the DNA-binding activity of Stat3. Collectively, these results suggest that both Stat3 and AKT provide survival signals in U87 and D54 cells, and Ser/Thr phosphorylation of Stat3-TAD by the PI3K-AKT pathway negatively controls the DNA-binding function of Stat3.
Introduction
Gliomas are the most common primary tumors of the central nervous system, which originate from astrocytes or their precursor cells including neural stem cells (Rasheed et al., 1999; Holland, 2000; Maher et al., 2001; Wechsler-Reya and Scott, 2001; Zhu and Parada, 2002; Singh et al., 2004a, b) . Gliomas are clinically classified into four grades, of which glioblastoma multiforme (GBM), grade IV is the most aggressive malignant tumor, with a median survival of less than a year (Rasheed et al., 1999; Holland, 2000; Maher et al., 2001) . GBM may be progressive arising from lowergrade gliomas or it may develop de novo; however, they behave in a clinically indistinguishable manner (Rasheed et al., 1999; Holland, 2000; Maher et al., 2001; Wechsler-Reya and Scott, 2001) . Genetic alterations that are frequently found in GBM cells include loss-offunction mutations or silencing of p53, p16, Rb and PTEN and gain-of-function mutations and/or amplification of the EGFR gene (Rasheed et al., 1999; Holland, 2000; Maher et al., 2001; Wechsler-Reya and Scott, 2001; Zhu and Parada, 2002) . These result in the deregulation of multiple intracellular signal transduction pathways leading to an enhanced cell proliferation, survival, tissue invasion and tumor angiogenesis, which are the cardinal features of GBM (Rasheed et al., 1999; Holland, 2000; Maher et al., 2001; Wechsler-Reya and Scott, 2001; Zhu and Parada, 2002; Rao, 2003) .
Suppression of spontaneous apoptosis and upregulation of cell division are most critical among the properties a somatic cell acquires in the course of its neoplastic transformation (Hanahan and Weinberg, 2000) . Spontaneous apoptosis may occur simultaneously with cell division to function as a failsafe mechanism that restrains inappropriate proliferation of somatic cells (Green and Evan, 2002) . It is a death receptorindependent apoptosis that occurs due to deprivation of external or internal survival signals (Green and Evan, 2002; Hanahan and Weinberg, 2000) . Activated PI3 kinase (PI3K)-AKT pathway provides major survival signals in GBM and many other cancer cells (Datta et al., 1999; Holland, 2000; Maher et al., 2001; Wechsler-Reya and Scott, 2001 ). Recently, we have shown that activated Stat3 is persistently present in both GBM primary tumors and cell lines, and inactivation of Stat3 reduces cell proliferation and induces spontaneous apoptosis in the GBM cell line U251 (Rahaman et al., 2002) . We have also found that persistent activation of Stat3 in U251 cells is, in part, mediated by autocrine IL-6 signaling (Rahaman et al., 2002) .
Here, we show that persistent activation of Stat3 in U87 and D54 cells is mediated by activated EGFR not IL-6 receptor complex, although these cells produce IL-6 (Van Meir et al., 1990; Goswami et al., 1998; Rolhion et al., 2001; Tchirkov et al., 2001; Rahaman et al., 2002) . Amplification and subsequent overexpression of the EGFR gene are present in B50% of GBM in adults (Wong et al., 1987 (Wong et al., , 1992 Ekstrand et al., 1991; Maher et al., 2001; Wechsler-Reya and Scott, 2001) . The EGFR gene is overexpressed in B30% of pediatric GBM in the absence of gene amplification (Fry et al., 1994; Aldape et al., 2004) . Approximately 40% of GBM that have EGFR amplification express a mutant EGFR known as EGFR vIII that lacks the functional ligand-binding domain due to a deletion spanning exons 2-7 (Rasheed et al., 1999; Holland, 2000; Maher et al., 2001; Aldape et al., 2004) . EGFR vIII becomes persistently activated at significantly low levels compared with ligand-dependent activation of the wild-type receptor (Rasheed et al., 1999; Holland, 2000; Maher et al., 2001; Aldape et al., 2004) . GBM also express EGF and TGF-a that activate EGFR by an autocrine manner (Ekstrand et al., 1991; Maher et al., 2001; Wechsler-Reya and Scott, 2001) . In GBM cells, EGFR also activates PI3K-AKT and Ras-MAPK pathways, both of which are found to enhance the proliferation and survival of many cancer cells (Wong et al., 1987; Catlett-Falcone et al., 1999; Grandis et al., 2000; Ballif and Blenis, 2001 ). Thus, multiple signaling pathways can support the proliferation and survival of a given cancer cell. There is an emerging concept that all intracellular signaling cascades do not follow linear paths to their destinations, rather they form a network of signaling circuits leading to a complex regulation of cell functions (Hanahan and Weinberg, 2000) .
In this article, we evaluate the relative contributions of AKT and Stat3 in the suppression of spontaneous apoptosis in U87 cells and uncovered a novel molecular mechanism by which the EGFR-activated PI3K-AKT pathway negatively regulates the DNA-binding function of Stat3 in U87 and D54 cells. Like all other Stat-family members, latent Stat3 molecules become activated by phosphorylation on Tyr 705 in cytokine/ growth factor-stimulated cells. Activated Stat3 molecules form homodimers that migrate to the nucleus, bind to cognate DNA elements and drive the transcription of target genes (Wong et al., 1987; Brivanlou and Darnell, 2002) . Here, we demonstrate that AKTdependent phosphorylation of multiple Ser/Thr residues in the Stat3 transactivation domain (TAD) downregulates the DNA-binding function of Stat3 without affecting the phosphorylation level of Tyr 705 .
Results

EGFR is a major activator of Stat3 in U87 and D54 cells
More than 90% of GBM primary tumors and all the GBM cell lines that we examined contained persistently activated Stat3 (Rahaman et al., 2002) . Stat3 becomes activated, in general, by the IL-6-family cytokines including IL-6 itself, LIF, CNTF and OSM, and also by a variety of growth factors that include EGF, PDGF, HGF and G-CSF (Wong et al., 1987; Heinrich et al., 2003) . Many cancer cells acquire growth advantage by producing cytokines and growth factors that act in an autocrine manner (Catlett-Falcone et al., 1999; Grandis et al., 2000; Hanahan and Weinberg, 2000) . Both GBM cell lines and primary tumors secrete IL-6 (Van Meir et al., 1990; Goswami et al., 1998; Rolhion et al., 2001; Tchirkov et al., 2001; Rahaman et al., 2002) . Previously, we have shown that the GBM cell line U251 persistently activates Stat3 by an autocrine action of IL-6 (Rahaman et al., 2002) .
Here, we show that unlike U251 (and T98G cells), U87 and D54 cells were refractory to Stat3 activation by IL-6 (Figure 1a ). Stat3 activation was measured by electrophoretic mobility shift assay (EMSA) using a radiolabeled sis (PDGF)-inducible element (SIE) derived from the promoter of human c-fos protooncogene, which binds to the homodimers of Stat3 (SIF-A), heterodimers of Stat1 and Stat3 (SIF-B) and homodimers of Stat1 (SIF-A) (Wagner et al., 1990; Catlett-Falcone et al., 1999) . EMSA-supershift experiments were performed using antibodies that were specific for Stat1, Stat3 and Stat5. DNA-protein complexes detected in U87 and D54 cells contained Stat3 homodimers as a major component of SIF complexes, although Stat1 homodimers or Stat1-Stat3 heterodimers were also detectable at lower levels ( Figure 1b) . To show the relative migration of SIF complexes, we used extracts of U87 and D54 cells that were exposed to 200 mM pervanadate for 30 min, which inhibited protein tyrosine phosphatase activity and induced all three SIF complexes (Haque et al., 1997) . Stat5-specific antibody served as a negative control (Rahaman et al., 2002) .
IL-6-mediated activation of Stat3 requires the activation of at least one of the Janus (JAK)-family tyrosine kinases that include Jak1, Jak2 and Tyk2, which remains constitutively associated with IL-6 signaling transmembrane protein gp130 . We noted that AG490, a Jak-specific inhibitor that inhibited Stat3 activation in U251 cells (Rahaman et al., 2002) failed to inhibit Stat3 activation in U87 cells in vitro, indicating that IL-6 signaling pathway was not functional in U87 cells (Figure 1c) . A similar observation was made in vivo where convection-enhanced delivery of AG490 reduced the growth of U251 cellderived tumors but not U87 cell-derived tumors in rat orthotopic xenograft model (SJ Haque and MA Vogelbaum, unpublished data) .
This raises the question: How does Stat3 become activated in U87 and D54 cells? EGFR activates Stat3 in many cell types (Wong et al., 1987; Grandis et al., 2000; Brivanlou and Darnell, 2002) . EGFR is persistently activated in B50% of GBM tumors due to an autocrine action of its ligands, amplification or overexpression of EGFR gene and/or gain-of-function mutation of the EGFR gene (EGFR vIII) (Rasheed et al., 1999; Holland, 2000; Maher et al., 2001; Wechsler-Reya and Scott, 2001; Zhu and Parada, 2002; Aldape et al., 2004) . We examined the possibility that EGFR was involved in the activation of Stat3 in U87 and D54 cells. U87 cells were treated with either EGF (100 ng/ml) or TGF-a (20 ng/ ml) for 10 and 20 min, and Stat3 activation was measured by EMSA. We found that ligand-dependent activation of EGFR significantly increased the activated Stat3 content over the constitutive basal level (Figure 1d, upper panel) . Further, to demonstrate that (a) GBM cell lines U87, D54, U251 and T98G were cultured for 3 h in serum-free medium prior to treatment with IL-6 (50 ng/ml) for indicated lengths of time, and WCEs were prepared. WCEs containing 10 mg proteins were subjected to EMSA using 0.2 ng of 32 P-labeled hSIE probe as described in 'Materials and methods'. (b) WCEs (10 mg) derived from U87 and D54 cells were incubated with either no antibody or 2.0 mg of anti-Stat1, anti-Stat3 or anti-Stat5 antibody for 20 min at room temperature prior to the addition of radiolabeled hSIE probe. To show the relative migration of SIF complexes, WCEs were prepared from U87 and D54 cells that were exposed to 200 mM pervanadate for 30 min, which induced all three SIF complexes. Stat5-specific antibody served as a negative control in EMSA supershift experiments. (c) U87 cells were treated with varying concentrations of AG490 for 48 h in serum-free medium and WCEs containing 10 mg of proteins were subjected to EMSA. (d) Upper panel: U87 cells were treated with 100 ng/ml EGF or 10 ng/ml of TGF-a in serum-free medium for indicated time periods and WCEs containing 10 mg protein were subjected to EMSA. Lower panel: U87 cells were pretreated with DMSO (vehicle), 10 mM PD153035 or 10 mM AG1478 for 30 min prior to treatment with 100 ng/ml EGF for 20 min. WCLs containing 1.0 mg protein were used for immunoprecipitation using anti-EGFR antibody followed by immunoblotting for phosho-Tyr. The blot was stripped and reprobed with anti-EGFR antibody. (e) U87 (upper panel) and D54 cells (lower panel) were treated with 10 mM PD153035 in serum-free medium for indicated periods of time and WCEs containing 10 mg of proteins were subjected to EMSA. WCLs containing 50 mg proteins were used for Western blot analyses using anti-Stat3 and anti-actin antibodies. (f) U87 (upper panel) and D54 cells (lower panel) were treated with 10 mM AG1478 in serum-free medium for indicated periods of time and WCEs containing 10 mg of proteins were subjected to EMSA Stat3 regulation by PI3K-AKT in GBM cells MK Ghosh et al persistent activation of Stat3 in U87 and D54 cells was mediated by the constitutive activation of EGFR, two pharmacologic inhibitors of EGFR, PD153035 and AG1478, were employed in the following experiments (Fry et al., 1994) . First, to test if these compounds inhibited Tyr phosphorylation (activation) of EFGR, U87 cells were pretreated with either PD153035 (10 mM) or AG1478 (10 mM) followed by treatment with 100 ng/ ml of EGF for 20 min (since the constitutive Tyr phosphorylation of EGFR was below a detectable level in U87 cells). EGFR was immunoprecipitated from cell lysates, resolved by SDS-PAGE and the resultant blot was probed with anti-phospho-tyrosine antibody ( Figure 1d , lower panel). The same blot was stripped and reprobed with anti-EGFR antibody to show the amount of total EGFR ( Figure 1d , lower panel). These data clearly demonstrate that EGFR activation resulted in the activation of Stat3 in U87 cells and EGFR activation was inhibited by PD153035 and AG1478. Wu et al. (2004) have also shown that Tyr phosphorylation of EGFR is inhibited by AG1478 in EGF-stimulated U87 cells, which supports our observation. We found that Stat3 activation was markedly inhibited within 3-6 h when EGFR activation was blocked by PD153035 in U87 and D54 cells ( Figure 1e ) without affecting the steady-state levels of Stat3. A similar observation was made when the cells were treated with AG1478 ( Figure 1f ). Taken together, these data indicate that Stat3 becomes activated in U87 and D54 cells via an activation of the EGFR pathway.
EGFR provides major survival signals through both Stat3 and AKT in U87 and D54 cells
We observed that PD153035 (10 mM) induced apoptosis in U87 cells after 6 h of treatment, as revealed by the proteolytic cleavage of poly-(ADP-ribose) polymerase (PARP) (Figure 2a ) (Pieper et al., 1999) , indicating that EGFR pathway was essential for the survival of these cells. EGFR also activated the PI3K-AKT pathway in U87 cells, since PD153035 significantly reduced the steady-state level of activated AKT (phospho-AKT) after 3 h ( Figure 2a ). PI3K-AKT pathway provides survival signals in a variety of normal and cancer cells (Datta et al., 1999) . As shown in Figure 2b , U87 cells that contained persistently activated AKT began to undergo apoptosis when exposed to LY294002, a potent inhibitor of PI3K (Fukuchi et al., 2000) for 6 h and AKT phosphorylation was completely blocked after 3 h. These data clearly indicate that PI3K-AKT pathway provides survival signal in U87 cells. We have previously shown that activated Stat3 suppresses spontaneous apoptosis of U251 cells (Rahaman et al., 2002) . These beg the question: Does activated Stat3 play a role in the survival of U87 cells? To address this, we generated stable U87 cell lines that expressed constitutively activated Stat3 (CA-Stat3) or dominant-negative mutant Stat3 (DN-Stat3). Substitution of two Cys residues for Ala 662 and Asn 664 within the C-terminal loop of the SH2 domain of Stat3 produces a mutant protein termed CA-Stat3 that dimerizes spontaneously, binds to DNA and activates transcription (Bromberg et al., 1999) . Cytokines and growth factors induce phosphorylation of Tyr 705 residue in Stat3 and a mutant Stat3 having Phe 705 substitution and thus lacking phosphorylation site is able to bind to phospho-Tyr on cytokine/growth factor receptors via its 
of three independent determinations
Stat3 regulation by PI3K-AKT in GBM cells MK Ghosh et al SH2 domain and inhibits the activation of endogenous Stat3 by acting as a DN-Stat3 protein (Zhong et al., 1994; Kaptein et al., 1996) . In subsequent experiments, two representative cell lines expressing CA-Stat3 (#9 and #15), DN-Stat3 (#6 and #14) and vector control (#3 and #5) were tested for the in vitro DNA-binding activity of activated Stat3 by EMSA. We noted that the CA-Stat3-expressing clones exhibited 3-4-fold increase in DNA-Stat3 complex formation, while the DN-Stat3-expressing clones harbored 4-5-fold decrease in DNAbinding activity of Stat3, as compared with the vector control cells (Figure 2c ). When these cells were treated with PD153035 to block the EGFR activation, >85% of vector control cells (#3) and >90% of DN-Stat3-expressing cells (#14) died after 18 h (Figure 2d ). By contrast, o70% CA-Stat3-expressing cells (#9) died after 18 h under the same condition of PD153035 treatment. When PI3K activity was blocked, instead, by LY294002, we noted B30% cell death in control cells (#3) and B20% cell death in CA-Stat3-expressing cells (#9), while >75% cells died in DN-Stat3-expressing cells (#14) (Figure 2d ). These data clearly suggest that Stat3 activation is required for the survival of U87 cells. EGFR also activated the Erk1/Erk2 MAPK pathway and blockade of this pathway by MEK1/MEK2 inhibitor U0126 (Favata et al., 1998) did not kill U87 cells after 18 h of treatment (data not shown). Thus, we show that both Stat3 and PI3K-AKT are required for the survival of U87 cells in vitro. We also noted that treatment of D54 cells with PD153035 for 24 h induced approximately 70-80% loss in cell viability, while similar treatment with LY294002 led to 25-35% loss in cell viability (data not shown).
PI3K-AKT pathway negatively controls the DNA-binding activity of Stat3 in both U87 and D54 cells Next the question arises: What are the downstream targets of these survival pathways? Previously, we have shown that antiapoptotic proteins Bcl-2, Bcl-X L and Mcl-1 are involved in the suppression of spontaneous apoptosis in U251 cells (Rahaman et al., 2002) . Here, we found that blockade of EGFR activation by PD153035 that killed >85% of U87 cells after 18 h, significantly reduced the steady-state level of Mcl-1 in a timedependent manner, while that of Bcl-2 and Bcl-X L were not significantly changed (Figure 3a) . However, blockade of the PI3K-AKT pathway by LY294002 that killed B30% of U87 cells after 18 h, significantly reduced Mcl-1 level between 6 and 15 h, which was increased at 24 h ( Figure 3b ). We noted that the number of viable U87 cells was reduced by LY294002 treatment up to 15-18 h, after that no further reduction in cell number was seen even in the presence of freshly added LY294002 (data not shown). Thus, it appears that Mcl-1 may have a critical role in the survival of U87 cells. Previously, we found that in U251 cells Mcl-1 expression is regulated by Stat3 (Rahaman et al., 2002) . Here, we asked if Stat3 was involved in the upregulation of Mcl-1 in U87 cells that were treated with LY294002 for 24 h. Accordingly, U87 cells were treated with LY294002 for varying lengths of time and the DNA-binding activity of Stat3 was determined by EMSA. We noted with surprise that in the absence of activated PI3K-AKT, the in vitro DNA-binding activity of Stat3 in U87 cells was significantly increased between 15 and 24 h (Figure 4a ), This observation was confirmed by treating U87 cells with another PI3K inhibitor Wartmannin (Sonoda et al., 1999; Fukuchi et al., 2000) (Figure 4a ). Similar results were obtained with D54 cells (Figure 4b ). To see if PI3K inhibition also increases the DNA-binding activity of Stat3 in vivo, D54 cells were treated with LY294002 (20 mM) or DMSO (vehicle) for 18 h, crosslinked with formaldehyde and 100 mg of isolated chromatin fragments (400-700 bp) were subjected to immunoprecipitation using two different anti-Stat3 antibodies. Immunoprecipitated chromatin was de-cross linked by boiling in Laemelli buffer, resolved by SDS-PAGE and resultant blot was probed with anti-Stat-3 antibody. Figure 4c shows that binding of Stat3 to chromatin was markedly enhanced when PI3K-AKT activity was inhibited in D54 cells. Interestingly, we found that the increase in DNA-binding activity of Stat3 in the absence of activated PI3K-AKT was not due to an increase in the phosphorylation of Tyr 705 as determined by Western analysis using anti-phospho-Tyr 705 -Stat3 antibody (Figure 4d ). In accord with these findings, when a constitutively active AKT protein (Burgering and Coffer, 1995) was overexpressed in a heterologous cell line 293T, it reduced the DNA-binding activity of Stat3, which was upregulated by LY294002 treatment 
DNA-binding activity of Stat3 is regulated by reversible phosphorylation of Ser/Thr residues located in the TAD
What is the molecular mechanism underlying the AKTmediated inhibition of the DNA-binding activity of Stat3? AKT is a Ser/Thr protein kinase (Datta et al., 1999) . AKT and/or protein kinases downstream of AKT may phosphorylate Stat3 on Ser/Thr residues. mTOR is shown to phosphorylate Ser 727 , which is located in the TAD of Stat3 (Yonezawa et al., 2004) . A number of studies have shown that Ser 727 phosphorylation upregulates the transcriptional activity of Stat3 (Wen et al., 1995; Decker and Kovarik, 2000) . Here, we noted that (i) even upon overexpression of the constitutively active AKT in 293T cells, the DNA-binding activity of Stat3 was not completely lost, and (ii) LY294002 treatment took a longer time to upregulate the DNA-binding activity of Stat3 than to block completely the PI3K-mediated activation of AKT. These suggest that AKTmediated downregulation of the DNA-binding activity of Stat3 is a regulated process. Given that this process involves Ser/Thr phosphorylation reaction, which is, in general, reversible in nature, it appears that a regulated, reversible Ser/Thr phosphorylation may negatively control the DNA-binding activity of Stat3. The reverse reaction in protein phosphorylation is catalysed by protein phosphatases. A recent study shows that protein phosphatase 2A (PP2A) inhibitor calyculin A (Cal-A) that stabilizes the Ser/Thr phosphorylation can reduce the DNA-binding activity of Stat3 (Woetmann et al., 1999) . This study has not addressed which kinase is involved or which residues become phosphorylated. We found that DNA-binding activity of Stat3 in U87 cells was inhibited by Cal-A with time and almost completely ablated at 60 min ( Figure 5a , upper panel). Similar results were obtained with 293T cells overexpressing WT-Stat3 (treated with 50 ng/ml IL-6 for 30 min) or CA-Stat3 after treatment with Cal-A (Figure 5a , middle panel). Cal-A has been shown to induce phosphorylation and activation of AKT in a variety of cell types (Andjelkovic et al., 1996; Meier et al., 1998; Resjo et al., 2002) . We noted that treatment of U87 and 293T cells with Cal-A induced significant activation of AKT without changing the level of total AKT (Figure 5a , bottom panel). Next, we asked where the phosphorylation site(s) in the Stat3 were located.
Multiple Ser/Thr residues located in TAD are involved in the regulation of Stat3's DNA-binding activity
Recently, we found that phosphorylation of multiple Ser residues in the transactivation domain another Statfamily member Stat6 reduces its DNA-binding activity in IL-4-stimulated cells Cal-A-mediated inhibition of Stat3's DNA-binding activity was reciprocally associated with the size of C-terminal truncation of Stat3, suggesting that phosphorylation of multiple Ser/Thr residues located in the Stat3-TAD is responsible for the inhibition of its DNAbinding activity (Figure 5c, lower panel) .
To demonstrate the in vitro phosphorylation of Ser/Thr residues in the Stat3-TAD, we generated fusion constructs of glutathione-S transferase (GST) and Stat3-TAD that encodes 65 amino acids (amino acids 706-770) (Chen et al., 1998) , without or with Ser 727 Ala mutation. A control GST-Stat1-TAD fusion construct was also prepared. The recombinant fusion proteins (and GST control protein) were expressed in Escherichia coli, and purified by affinity chromatography. All the recombinant GST-fusion proteins were expressed at similar levels (Figure 6a ). Purified proteins and [g-32 P] ATP were used as substrates in an in vitro kinase assay with cell-free extracts derived from LY294002-or DMSO-treated U87 and D54 cells as described (DiDonato, 2000; Maiti et al., 2005) . As demonstrated in Figure 6b , GBM cell extract was able to phosphorylate Stat3-TAD but not Stat1-TAD. Importantly, the in vitro phosphorylation was decreased when the extracts were derived from LY294002-treated GBM cells. Moreover, Ser 727 Ala mutation did not affect the phosphorylation of Stat3-TAD (Figure 6c ). These data suggest that this phosphorylation is Stat3-TAD specific and independent of Ser 727 . Further mutagenesis studies are underway to map precisely the Ser/Thr residues that are phosphorylated by the PI3K-AKT pathway in GBM as well as other cancer cells. 
Discussion
Previously, we have shown that (i) all the GBM cell lines and >90% of GBM primary tumors examined contain constitutively activated Stat3 and (ii) activated Stat3 induces proliferation and suppresses spontaneous apoptosis in U251 cells (Rahaman et al., 2002) . In this article, we provide evidence that (i) all GBM cells that produce IL-6 are not responsive to its autocrine action, for example, IL-6 can activate Stat3 in U251 and T98G cells but not in U87 and D54 cells, (ii) U87 and D54 cells contain activated EGFR, which in turn activates Stat3, PI3K-AKT and Ras-Erk1/2 pathways, (iii) blockade of EGFR activation leads to the spontaneous apoptosis of U87 and D54 cells, which is largely due to the inactivation of both Stat3 and PI3K-AKT pathways that in turn downregulate the expression of Mcl-1, and finally, (iv) the PI3K-AKT pathway negatively controls the DNA-binding activity of Stat3 possibly by phosphorylating multiple Ser/Thr residues (excluding Ser 727 ) that are located in the Stat3-TAD. Unlike normal cells, tumor cells are self-sufficient in growth signals, which are mediated by an autocrine action of growth factors and cytokines or by aberrant activation of RTKs and inactivation of tumor suppressor genes (Hanahan and Weinberg, 2000) . These in turn persistently activate multiple intracellular signaling pathways contributing to the pathogenesis of cancer (Rasheed et al., 1999; Hanahan and Weinberg, 2000; Holland, 2000; Maher et al., 2001; Wechsler-Reya and Scott, 2001; Zhu and Parada, 2002) . A number of studies have demonstrated that malignant glioma cells express the IL-6 gene both in vivo and in vitro (Van Meir et al., 1990; Goswami et al., 1998; Rolhion et al., 2001; Tchirkov et al., 2001; Rahaman et al., 2002) . These studies have also suggested that the upregulation of IL-6 gene expression that often results from an amplification of the IL-6 gene could be correlated with the aggressiveness of human gliomas . Importantly, a recent study has demonstrated that IL-6 is required for the development of malignant gliomas in a mouse model (Weissenberger et al., 2004) . We found that unlike U251 and T98G cells, U87 and D54 cells are not fully responsive to exogenous IL-6 in vitro (Rahaman et al., 2002) . Binding of IL-6 to IL-6Ra leads to the activation of gp130-dependent intracellular Jak-Stat1/3 and the Erk1/2 MAPK pathways . However, in U87 cells, we found that the Jak-specific tyrosine kinase inhibitor AG490 fails to inhibit Stat3 activation both in vitro and in vivo in a rat orthotopic xenograft model (Haque and Vogelbaum, data not shown), suggesting that the persistent activation of Stat3 is not due to an autocrine action of IL-6. Goswami et al. (1998) has noted that inhibition of IL-6 production reduces the growth of U87 cells. This discrepancy might be due to the clonal variation of U87 cell line. We found that inhibition of autocrine IL-6 signaling reduces the growth of U251 cells with a concomitant reduction of Stat3 activation (Rahaman et al., 2002) . In U87 and D54 cells, Stat3 is activated through the EGFR pathway, which could be completely blocked by EFGR inhibitor PD153035 or AG1478. In U87 cells, EGFR activates three major intracellular pathways, namely, PI3K-AKT, Ras-Erk1/2 and Stat3. Thus, it is important to evaluate the relative contributions of these pathways in the enhanced proliferation and survival of these cells. Preliminary experiments reveal that blockade of the Erk1/2 pathway in U87 cells by MEK1/2 inhibitor U0126 does not induce apoptosis, although it blocks cell cycle progression (data not shown). Given that the PI3K-AKT pathway functions as a major survival pathway in many cells types, both normal and cancer (Datta et al., 1999) , and since blockade of this pathway induces spontaneous apoptosis in U87 cells, the question arises: Does activated Stat3 have a role in the survival of U87 cells? Stable expression of dominant-negative mutant Stat3 makes U87 cells more susceptible to spontaneous apoptosis in the absence of PI3K-AKT activation than in the presence of PI3K-AKT activation, which clearly indicates that Stat3 activation is required for the survival U87 cells. Thus, it appears that no matter how it is activated, Stat3 is an essential player in keeping the apoptosis machinery at bay in GBM cells, and possibly does so by maintaining the expression of the prosurvival proteins Mcl-1 in U87 cells and Mcl-1, Bcl-2 and Bcl-X L in U251 cells (Rahaman et al., 2002) . More recently, we show by chromatin immunoprecipitation employing anti-Stat3 antibody that activated Stat3 remains bound to the promoters of these prosurvival genes in GBM cells (Rahaman et al., 2005) . PI3K-AKT pathway also upregulates the expression of mcl-1 and bcl-2 genes (Ballif and Blenis, 2001), suggesting that both Stat3 and PI3K-AKT target the same prosurvival genes. There is an emerging concept that intracellular signaling pathways, which originate at the cell surface receptors and culminate in the nucleus, do not always follow linear paths (Hanahan and Weinberg, 2000) . Here, we have clearly demonstrated that the PI3K-AKT pathway crosstalks with the EGFR-Stat3 pathway and negatively controls the DNA-binding activity of Stat3. Now a key question arises: What are the molecular mechanisms underlying the negative regulation of Stat3's DNAbinding function by the PI3K-AKT pathway?
It has initially been established that the magnitude of Stat3's DNA-binding activity is a function of its dimer formation (Brivanlou and Darnell, 2002) . It is also noted that phosphorylation of Ser 727 located in the TAD can positively control the DNA-binding activity and transcriptional potential of Stat3 (Wen et al., 1995; Decker and Kovarik, 2000) . However, it is also shown that phosphorylation of Ser 727 reduces the DNAbinding activity of Stat3 (Decker and Kovarik, 2000) . A recent study shows that Ser/Thr phosphorylation of Stat3 negatively controls its DNA-binding activity, which is a tightly regulated reversible process and can be stabilized by treating the cells with inhibitors of PP2A (Woetmann et al., 1999) . We find that phosphorylation of multiple Ser residues located in the TAD of Stat6 negatively controls its DNA-binding activity in IL-4-stimulated cells . Accordingly, we have generated C-terminal deletions of the Stat3-TAD and found that multiple Ser/Thr residues become phosphorylated in PP2A-inhibited cells leading to an inhibition of Stat3's DNA-binding activity. This suggests that the PI3K-AKT pathway indirectly or directly phosphorylates the Ser/Thr residues in the Stat3-TAD, which in turn inhibits its DNA-binding activity. Based on these findings, we propose a model for Stat3 function and its regulation in GBM cells (Figure 7) . According to this model, activated EGFR suppresses the spontaneous apoptosis of U87 or D54 cells by upregulating the expression of the prosurvival proteins like Mcl-1 through the activation of both PI3K-AKT and Stat3 pathways. However, the former is not a linear pathway, it crosstalks with the Stat3 pathway and negatively regulates Stat3's DNA-binding activity. This negative control is further inhibited by cellular PP2A activity, which is again under the negative control of mTOR, a Ser/Thr kinase downstream of AKT (Datta et al., 1999; Haque et al., 2000) . Alternatively, the DNA-binding activity of Stat3 could be negatively controlled by binding of Tyr 705 -phosphorylated Stat3 with the forkhead (FKHR)-family of transcription factors that are phosphorylated by AKT (Datta et al., 1999) . A recent study has shown that Stat3 physically associates with FHKR when overexpressed in hepatoma cells and other studies have shown that AKT, which is required for the expression of the Bcl-2-family proteins, does phosphorylate FKHR (Datta et al., 1999; Kortylewski et al., 2003) . As we find that blockade of PI3K-AKT pathway in U87 cells by LY294002 occurs within 3 h but upregulation of Stat3 and concomitant restoration of Mcl-1 expression take B15 h, it will be interesting to explore the possibility that sequestration of activated Stat3 by FKHR is also responsible for the negative regulation of Stat3's DNA-binding activity.
Materials and methods
Cell culture and reagents
GBM cell lines U87, D54, U251 and T98G and human embryonic kidney cell line 293T were cultured in DMEM (Bromberg et al., 1999) , dominant-negative mutant Stat3 (containing Tyr 705 Phe mutation) (Zhong et al., 1994; Kaptein et al., 1996) or an empty vector pCDNA3.1-Hygro( þ ) DNA, by using Lipofectamine-Plus reagent (Invitrogen) according to the manufacturer's instructions. Stable clones were selected using 50 mg/ml of hygromycin B for 2-3 weeks. 293T cells (10 6 cells/10 cm plate) were transiently transfected with indicated plasmid DNA by using calcium phosphate method as described .
Electrophoretic mobility shift assay
Cells were grown to an appropriate density in serum containing media. After treatment with indicated reagents in serumfree medium, whole-cell extracts (WCEs) were prepared as described previously . EMSA was performed using 10-15 mg of WCE protein and 0.2 ng of 32 P-labeled high-affinity hSIE probe (top strand: 5 0 -TCGA-CATTTCCCGTAAATC-3 0 ) derived from the c-fos gene promoter (Wagner et al., 1990; Catlett-Falcone et al., 1999) . For EMSA-supershift assay, WCE were incubated with polyclonal antibody specific for Stat1, Stat3 or Stat5 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) prior to the addition of radiolabeled probe, which was followed by 20 min incubation at room temperature.
Immunoprecipitation and Western blot analyses
To determine effects of pharmacologic inhibitors on EGFR phosphorylation, U87 cells were pretreated with DMSO (vehicle), 10 mM PD153035 or 10 mM AG1478 for 30 min followed by treatment with 100 ng/ml of EGF for 20 min.
Tyr phosphorylation of EGFR was measured as described (Wu et al., 2004) . Briefly, 1.0 mg protein was used for immunoprecipitation with anti-EGFR antibody (Santa Cruz Biotechnology) followed by Western blotting with antiphospho-Tyr antibody (clone pY-100; Cell Signaling, Beverly, MA, USA). The blot was stripped and reprobed with anti-EGFR antibody.
For direct detection of protein levels, whole-cell lysates (WCLs) were prepared by lysing the cells in ice-cold buffer containing 50 mM Tris, pH 7.9, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 1% NP-40, 10% glycerol, 1 mM PMSF, 2 mg/ml Leupeptin, 2 mg/ml Pepstatin, 5 mg/ml Aprotinin on ice for 30 min. SDS-PAGE and Western blot analyses were performed using standard procedures. Antibodies for phosphoStat3 (Y-705), phospho-AKT (Ser-473), AKT and PARP were purchased from Cell Signaling. Antibodies for Bcl-2, Mcl-1 and actin were from Santa Cruz Biotechnology. Anti-Bcl-X L antibody was from Transduction Laboratories (Franklin Lakes, NJ, USA). Blots were evaluated by using Enhanced Chemi-luminescence plus reagent according to the manufacturer's manual (Amersham Pharmacia, Piscataway, NJ, USA).
Chromatin immunoprecipitation
To determine chromatin-Stat3 interaction in vivo, D54 cells were treated with DMSO (vehicle) or LY294002 (20 mM) for 18 h in serum-free medium. Preparation and immunoprecipitation of chromatin were performed as described (Ghosh and Harter, 2003) using two different anti-Stat3 antibodies (antibody 1 was from Santa Cruz and antibody 2 from Zymed). Briefly, 10 8 cells were crosslinked with formaldehyde, and the chromatin from these cells were sonicated to generate an average length of 400-700 bp. CsCl-purified chromatin (100 mg) were precleared and immunoprecipitated using 2.0 mg of indicated antibody. Washed chromatin immunoprecipitate was decrosslinked by boiling in Lamelli buffer for 30 min followed by Western blotting with anti-Stat3 antibody from Zymed.
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